2026-04-14T04:52:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/109422025-10-24T10:21:39Zcom_2072_378070com_2072_378040col_2072_378092

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer Rudin, Charles Liu, Stephen Soo, Ross Lu, Shun Hong, Min Hee Lee, Jong Seok NAVARRO, ALEJANDRO Institut Català de la Salut [Rudin CM] Memorial Sloan Kettering Cancer Center, New York, NY. [Liu SV] Georgetown University, Washington, DC. [Soo RA] National University Cancer Institute, Singapore, Singapore. [Lu S] Shanghai Chest Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China. [Hong MH] Yonsei Cancer Center, Severance Hospital, Seoul, South Korea. [Lee JS] Seoul National University Bundang Hospital, Seongnam, South Korea. [Navarro A] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Anticossos monoclonals - Ús terapèutic Quimioteràpia Pulmons - Càncer - Tractament DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Small Cell Lung Carcinoma ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma pulmonar de células pequeñas TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales Tiragolumab; Chemotherapy; Small-cell lung cancer Tiragolumab; Quimioteràpia; Càncer de pulmó de cèl·lules petites Tiragolumab; Quimioterapia; Cáncer de pulmón de células pequeñas Purpose The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses. Methods Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary end points were investigator-assessed PFS and OS in patients without history/presence of brain metastases (primary analysis set [PAS]). Additional end points included PFS and OS in all patients regardless of brain metastases status (full analysis set [FAS]), response, and safety. Results Four hundred ninety patients were randomly assigned (FAS): 243 to tiragolumab arm and 247 to control arm. At the cutoff date (February 6, 2022; median duration of follow-up, 14.3 months [PAS] and 13.9 months [FAS]), final analysis of PFS in the PAS (n = 397) did not reach statistical significance (stratified hazard ratio [HR], 1.11; P = .3504; median, 5.4 months tiragolumab v 5.6 months control). At the cutoff date (September 6, 2022; median duration of follow-up, 21.2 months [FAS]), median OS in the PAS at final OS analysis was 13.1 months in both arms (stratified HR, 1.14; P = .2859). Median PFS and OS in the FAS were consistent with the PAS. The proportion of patients with immune-mediated adverse events (AEs) in the tiragolumab and control arms was 54.4% and 49.2%, respectively (grade 3/4: 7.9% and 7.7%). AEs leading to treatment withdrawal occurred in 8.4% and 9.3% of tiragolumab- and control-treated patients, respectively. Conclusion Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals. Supported by Genentech Inc and F. Hoffmann-La Roche Ltd. C.M.D.'s work on small cell lung cancer is supported by NIH R35CA263816, U24CA13274, and P30CA008748. 2024-01-31T13:08:25Z 2024-01-31T13:08:25Z 2024-01-20 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2024 Jan 20;42(3):324–35. 1527-7755 https://hdl.handle.net/11351/10942 10.1200/JCO.23.01363 37976444 http://hdl.handle.net/11351/10942 eng Journal of Clinical Oncologyncology;42(3) https://doi.org/10.1200/JCO.23.01363 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf American Society of Clinical Oncology Scientia